

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

December 9, 2019  
Date of Report (Date of earliest event reported)

---

**Sophiris Bio Inc.**

(Exact name of registrant as specified in its charter)

---

**British Columbia**

(State or other jurisdiction  
of incorporation)

---

**001-36054**

(Commission File Number)

---

**98-1008712**

(IRS Employer Identification No.)

**1258 Prospect Street  
La Jolla, CA**

(Address of principal executive offices)

**92037**

(Zip Code)

**Registrant's telephone number, including area code: (858) 777-1760**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
<b>Common Shares, no par value</b>	<b>SPHS</b>	<b>The Nasdaq Capital Market</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 9, 2019, Dr. Allison Hulme tendered her resignation as Chief Operating Officer and Head of Research and Development to pursue another business opportunity. Dr. Hulme's resignation will be effective December 31, 2019. Dr. Hulme will remain in her position as a director of the Company.

Effective January 1, 2020, the Company and Dr. Hulme plan to enter into a consulting agreement under which Dr. Hulme will provide certain services to the Company, including services related to investor and partnering discussions and the Company's development and regulatory program and strategies.

Effective January 1, 2020, Dr. Hulme will begin to receive compensation under the Company's Non-Employee Director Compensation Plan. As permitted under the Company's 2011 Stock Option Plan, Dr. Hulme's outstanding options will remain in place and the options will continue to vest in accordance with the original option awards.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Sophiris Bio Inc.**

Dated: December 13, 2019

By: /s/ Peter Slover  
Peter Slover  
Chief Financial Officer